R & D

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

 This material is intended to notify the press release issued on May 6 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click for the original press release.